Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Mar;61(3):409-411.
doi: 10.1111/head.14086.

Migraine treatment and COVID-19 vaccines: No cause for concern

Amy A Gelfand  1 , Gregory Poland  2
Affiliations
Editorial

Migraine treatment and COVID-19 vaccines: No cause for concern

Amy A Gelfand et al. Headache. 2021 Mar.
No abstract available

Keywords: coronavirus disease 2019; migraine; vaccine.

PubMed Disclaimer

Conflict of interest statement

AAG: In the last 12 months, Dr. Gelfand has received honoraria from UpToDate (for authorship) and JAMA Neurology. She receives payment from the American Headache Society for her role as Editor of Headache. She receives grant support from Amgen and the Duke Clinical Research Institute. Her spouse reports research support (to UCSF) from Genentech for a clinical trial, honoraria for editorial work from Dynamed Plus, and personal compensation for medical‐legal consulting. GP: Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergent Biosolutions, Dynavax, Genentech, Eli Lilly and Company, Janssen Global Services LLC, Kentucky Bioprocessing, AstraZeneca, and Genevant Sciences, Inc. Dr. Poland holds patents related to vaccinia and measles peptide vaccines. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide‐based COVID‐19 vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies.

Similar articles

See all similar articles

Cited by

References

    1. Zhang R. FDA Review of Efficacy and Safety of Moderna COVID‐19 Vaccine Emergency Use Authorization Request; 2020. https://www.fda.gov/media/144585/download. Accessed January 26, 2021.
    1. Assas BM, Pennock JI, Miyan JA. Calcitonin gene‐related peptide is a key neurotransmitter in the neuro‐immune axis. Front Neurosci. 2014;8:23. - PMC - PubMed
    1. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol. 1999;29(8):2613‐2624. - PubMed
    1. Deng H, Li GG, Nie H, et al. Efficacy and safety of calcitonin‐gene‐related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine—an updated systematic review and meta‐analysis. BMC Neurol. 2020;20(1):57. - PMC - PubMed
    1. Han L, Liu Y, Xiong H, Hong P. CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta‐analysis. Brain Behav. 2019;9(2):e01215. - PMC - PubMed

Publication types

Substances